The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > BUSINESS
BUSINESS
- DSP to Acquire Boston Biomedical, US Bioventure Specializing in Oncology
March 1, 2012
- Nippon Kayaku Applies for Vascular Embolizing Agent NK939
March 1, 2012
- “It Is Time for Ranbaxy to Regain Brilliancy”: Daiichi Sankyo
February 29, 2012
- MTPC to Reorganize Product Marketing Dept. Aiming at Early Market Penetration of New Products
February 29, 2012
- Pfizer Japan to Set Up Rare Disease Division
February 29, 2012
- IMS Japan VP Miyoshi Calls for Focus Shift from Long-Listed Products to Abolishment of Post-Market Expansion Re-Pricing
February 29, 2012
- OTS102 Fails to Prolong Survival in Pancreatic Cancer: OncoTherapy Science
February 29, 2012
- Wakamoto to Comarket Bausch & Lomb’s Ocuvite Series of Eye Supplements from April 1
February 29, 2012
- Major European, US Drug Makers Turning Sights Toward “Mini-buster” Drugs for Rare Diseases
February 29, 2012
- Sanofi Pasteur Files for Approval for Monovalent IPV
February 27, 2012
- Novartis Pharma Submits Afinitor for Add’l Indication of Tuberous Sclerosis
February 27, 2012
- EMA Accepts MAA for Peginesatide for Treatment of Anemia Associated with CKD: Takeda
February 27, 2012
- JCR Pharmaceuticals Announces Favorable Results from PI/II Trial of Stem-cell-based Therapy
February 27, 2012
- Diabetes Treatments: Their Development and Market (2)
February 27, 2012
- Daiichi Sankyo and Terumo Codevelop Intradermal Vaccine
February 24, 2012
- Nichi-Iko and Pfizer Japan Obtain Approval for Cisplatin Generic for Indication of Biliary Tract Cancer
February 24, 2012
- Ajinomoto Pharm. Files NDA for New Oral Bowel Cleansing Agent in Japan
February 24, 2012
- SymBio’s Licensee InnoPharmax Launches Bendamustine in Taiwan
February 24, 2012
- Eli Lilly Receives Approval for Zyprexa, First for Depression in Bipolar Disorder
February 23, 2012
- Use of Rasilez in Combination with ACE Inhibitors, ARBs in Patients with Diabetes to Be Contraindicated in Europe: Novartis
February 23, 2012
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…